RxDoctor Payments Data

Sinnarajah Raguraj, MD

Internal Medicine · Bel Air, MDNPI 1578584405

Payments from drug & device makers

$19,397in general payments, 2019–2025

Across 1,209 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$19,26799%
  • Education$1301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)147$2,080
AstraZeneca98$1,800
Novo Nordisk89$1,427
Pfizer98$1,386
Lilly USA, LLC87$1,266
Amgen(2 entities)76$1,180
GSK65$1,048
Johnson & Johnson41$788
Boehringer Ingelheim49$744
Astellas Pharma US Inc31$543
Esperion Therapeutics, Inc.31$454
Amarin Pharma, Inc.34$398
Amneal Pharmaceuticals LLC26$358
E.r. Squibb & Sons, L.L.C.20$344
Takeda Pharmaceuticals U.S.A., Inc.20$320
Sanofi-aventis U.S. LLC18$300
Otsuka America Pharmaceutical, Inc.15$287
Bayer17$282
Merck17$247
Sumitomo Pharma America, Inc.11$233
Teva Pharmaceuticals USA, Inc.14$232
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC14$213
Kowa Pharmaceuticals America, Inc.15$209
Jazz Pharmaceuticals Inc.13$209
Exact Sciences10$204
Novartis12$186
Antares Pharma, Inc.10$156
Biohaven Pharmaceutical Holding Company Ltd.8$152
Arbor Pharmaceuticals, Inc.5$145
Lundbeck LLC6$145
Phathom Pharmaceuticals, Inc.7$122
Xeris Pharmaceuticals, Inc.6$119
Abbott7$111
Teleflex LLC1$111
Sunovion Pharmaceuticals Inc.6$102
Corcept Therapeutics5$96
Biohaven Pharmaceuticals, Inc.6$93
Axsome Therapeutics, Inc.4$92
Idorsia Pharmaceuticals US Inc5$88
Almatica Pharma LLC4$82
Neos Therapeutics, LP4$69
Viatris Specialty LLC3$65
Azurity Pharmaceuticals, Inc.3$58
Ironwood Pharmaceuticals, Inc4$57
Hikma Pharmaceuticals USA4$53
Acerus Pharmaceuticals Corporation3$53
Supernus Pharmaceuticals, Inc.3$50
Sanofi Pasteur Inc.3$49
Evoke Pharma, Inc.3$48
Zyla Life Sciences, Inc.3$46
Nevro Corp.2$43
Adlon Therapeutics L.p.3$43
Shire North American Group Inc2$39
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$32
Agios Pharmaceuticals, Inc.1$32
Kaleo, Inc.2$32
Ironshore Pharmaceuticals Inc.2$31
Optinose US, Inc.2$31
Aytu Biopharma, Inc.2$29
Globus Medical1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,397 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$245,756
Medicare patients
522
Services billed
3,866

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$124,884
OzempicSemaglutide29$53,550
FarxigaDapagliflozin Propanediol43$51,040
JardianceEmpagliflozin35$47,763
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$46,288
XareltoRivaroxaban22$38,283
RybelsusSemaglutide13$31,075
JanumetSitagliptin Phos/Metformin Hcl18$24,205
JanuviaSitagliptin Phosphate18$18,925
Janumet XrSitagliptin Phos/Metformin Hcl13$14,000
MyrbetriqMirabegron13$11,652
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$10,005
SynthroidLevothyroxine Sodium74$8,671
BrilintaTicagrelor13$7,628
Rosuvastatin Calcium332$7,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,386$124,88489 claims
Novo NordiskOzempic, Rybelsus$1,427$84,62542 claims
AstraZenecaFarxiga, Brilinta$1,800$58,66856 claims
MerckJanumet, Januvia, Janumet Xr$247$57,12949 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,048$56,29341 claims
Boehringer IngelheimJardiance$744$47,76335 claims
Johnson & JohnsonXarelto$788$38,28322 claims
Astellas Pharma US IncMyrbetriq$543$11,65213 claims
AbbVieSynthroid$2,080$8,67174 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$358$3,632291 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Bel Air

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →